XOMA (NASDAQ:XOMA) Shares Pass Above 200 Day Moving Average of $20.30

XOMA Co. (NASDAQ:XOMA)’s share price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $20.30 and traded as high as $26.14. XOMA shares last traded at $25.64, with a volume of 8,219 shares changing hands.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $74.00 price objective on shares of XOMA in a report on Friday, February 16th.

XOMA Stock Down 1.7 %

The company has a quick ratio of 8.68, a current ratio of 8.68 and a debt-to-equity ratio of 1.34. The company has a market cap of $298.45 million, a price-to-earnings ratio of -6.35 and a beta of 0.58. The business has a 50-day simple moving average of $24.69 and a two-hundred day simple moving average of $20.30.

XOMA (NASDAQ:XOMA) last posted its earnings results on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). The firm had revenue of $1.83 million during the quarter, compared to analyst estimates of $1.01 million. XOMA had a negative net margin of 886.91% and a negative return on equity of 25.17%. As a group, equities analysts forecast that XOMA Co. will post -1.73 earnings per share for the current fiscal year.

Institutional Trading of XOMA

A hedge fund recently raised its stake in XOMA stock. Stonepine Capital Management LLC grew its stake in shares of XOMA Co. (NASDAQ:XOMA) by 25.0% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 436,602 shares of the biotechnology company’s stock after buying an additional 87,203 shares during the period. XOMA makes up 2.0% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 12th biggest holding. Stonepine Capital Management LLC owned about 3.80% of XOMA worth $6,152,000 as of its most recent filing with the SEC. Institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.